Classical complement pathway
part 13/17 · 26.4 KB total
──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
cite-note-99. ↑ citerefpleguezuelosstoloffcaparr-s-wanderley2013Pleguezuelos, Olga; Stoloff, Gregory A; Caparrós-Wanderley, Wilson (2013-04-04). "Synthetic immunotherapy induces HIV virus specific Th1 cytotoxic response and death of an HIV-1 infected human cell line through classic complement activation". Virology Journal. 10 (1): 107. doi:10.1186/1743-422x-10-107. PMC 3626621. PMID 23557359.
cite-note-1010. ↑ citerefanlidongwu2015An, Jingang; Li, Zhengxiao; Dong, Yingying; Wu, Jiawen; Ren, Jianwen (2015-05-22). "Complement activation contributes to the anti-methicillin-resistant Staphylococcus aureus effect of natural anti-keratin antibody". Biochemical and Biophysical Research Communications. 461 (1): 142–147. doi:10.1016/j.bbrc.2015.03.182. PMID 25862372.
──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────